WHITEHOUSE STATION, N.J., July 1, 2011 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved three products – GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant], ZOLINZA® vorinostat) and CUBICIN® (daptomycin for injection) – […]
‘Clinical trials of HPV vaccine conducted on tribal girls’
By Staff Reporter for ‘The Hindu’ KHAMMAM: Tribal woman P Venkatamma, mother of Sarita, the girl who died after receiving human papillomavirus (HPV) vaccine in Duggmugudem mandal last year, has appealed to the authorities concerned to make the postmortem report of her daughter accessible to her. Venkatamma along with several tribal women participated in a […]
Human Smears
By Madhavi Tata Poor Andhra villagers now victims of clinical drug trials. No Drug Resistance •35 women, some men from Guntur district put through clinical trials of a breast cancer drug. They later complain of joint pains, nausea and chest pains. •Biotech industry in Andhra is worth about Rs 455 crore (around $100 million) •Touts […]
India: deadly drug trials
By Jason Overdorf A $400 million market for clinical trials puts desperate Indian patients at risk. CHENNAI, India — India’s huge population, many of whom have hardly been exposed to medication, makes it one of the world’s most promising markets for drug research. But as the $400 million business accelerates, critics say it is exposing […]
Large patient pool in India for trials
The Times of India June 18, 2011 Factors such as skilled medical professionals, low-cost services, diverse genetic pool, large patient pool and world-class hospitals to undertake clinical trials are the reason for India becoming a favoured destination for such clinical trials. Andhra Pradesh accounts for almost 28 per cent of total trials in the country. […]
- « Previous Page
- 1
- …
- 20
- 21
- 22
- 23
- 24
- …
- 40
- Next Page »